Literature DB >> 8249278

Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein.

K Hertogs1, W P Leenders, E Depla, W C De Bruin, L Meheus, J Raymackers, H Moshage, S H Yap.   

Abstract

Binding of viral envelope proteins to specific receptors on human hepatocytes is considered to be an important step in HBV infection. In this study, we demonstrate that a 34-kDa human liver plasma membrane protein specifically binds to small HBsAg in a Ca(2+)-dependent manner. By partial amino acid sequence analysis of preparatively isolated 34-kDa protein comigrating with HBsAg-binding protein obtained from binding assay on IEF/SDS-PAGE, we have identified this HBsAg-binding protein as Endonexin II (E-II). Native human liver E-II inhibits binding of HBsAg to intact human hepatocytes and shows specific binding to small HBsAg. This binding can be inhibited by human liver plasma membrane proteins, recombinant E-II, or anti-E-II antibodies. Despite 90% sequence homology, rat liver E-II does not bind to small HBsAg and does not inhibit significantly (less than 20%) binding of HBsAg to intact hepatocytes. Cross-linking of small HBsAg and radiolabeled human liver E-II resulted in a specific additional protein complex on PAGE with an apparent molecular weight of 90 kDa, corresponding to a complex of E-II and small HBsAg with a ratio of 2 to 1 or 1 to 2. These findings indicate that E-II, found in human liver, is a specific HBsAg-binding protein and might play an important role in the initiation of HBV infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249278     DOI: 10.1006/viro.1993.1628

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

2.  An 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virus.

Authors:  C J Ryu; D Y Cho; P Gripon; H S Kim; C Guguen-Guillouzo; H J Hong
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 4.  Quantification of HBsAg: basic virology for clinical practice.

Authors:  Jung Min Lee; Sang Hoon Ahn
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

5.  Host cellular annexin II is associated with cytomegalovirus particles isolated from cultured human fibroblasts.

Authors:  J F Wright; A Kurosky; E L Pryzdial; S Wasi
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  Monoclonal antibodies to a 55-kilodalton protein present in duck liver inhibit infection of primary duck hepatocytes with duck hepatitis B virus.

Authors:  J T Guo; J C Pugh
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Interaction between duck hepatitis B virus and a 170-kilodalton cellular protein is mediated through a neutralizing epitope of the pre-S region and occurs during viral infection.

Authors:  S Tong; J Li; J R Wands
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 8.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

9.  Spontaneous development of anti-hepatitis B virus envelope (anti-idiotypic) antibodies in animals immunized with human liver endonexin II or with the F(ab')2 fragment of anti-human liver endonexin II immunoglobulin G: evidence for a receptor-ligand-like relationship between small hepatitis B surface antigen and endonexin II.

Authors:  K Hertogs; E Depla; T Crabbé; W De Bruin; W Leenders; H Moshage; S H Yap
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 10.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.